Effectiveness of BNT162b2 XBB Vaccine Against XBB and JN.1 Sublineages-Reference-Cited by-同舟云学术

Effectiveness of BNT162b2 XBB Vaccine Against XBB and JN.1 Sublineages

Published:2024-06-28 Issue:7 Volume:11 Page:
ISSN:2328-8957
Container-title:Open Forum Infectious Diseases
language:en
Short-container-title:

Author:

Tartof Sara Y¹^ORCID,Slezak Jeff M¹,Puzniak Laura²,Frankland Timothy B³,Ackerson Bradley K⁴^ORCID,Jodar Luis²^ORCID,McLaughlin John M²

Affiliation:

1. Department of Research and Evaluation, Kaiser Permanente Southern California , Pasadena, California , USA

2. Global Vaccines and Antivirals, Pfizer Inc , Collegeville, Pennsylvania , USA

3. Center for Integrated Health Care Research (CIHR), Kaiser Permanente Hawaii , Honolulu, Hawaii , USA

4. Department of Pediatric Infectious Diseases, Southern California Permanente Medical Group , Harbor City, California , USA

Abstract

Abstract We provide updated results (11 October 2023 through 29 February 2024) from our previously conducted test-negative case-control study in Kaiser Permanente Southern California to evaluate sublineage-specific effectiveness of the BNT162b2 XBB1.5-adapted vaccine. Results suggest that XBB1.5-adapted vaccines may have reduced effectiveness against JN.1 versus XBB sublineages.

Funder

Pfizer

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/ofid/advance-article-pdf/doi/10.1093/ofid/ofae370/58374459/ofae370.pdf

Reference14 articles.

1. XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1;Wang;Cell Host Microbe,2024

2. Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure;Yang;Lancet Infect Dis,2024

3. Effectiveness of the 2023–2024 formulation of the coronavirus disease 2019 mRNA vaccine [manuscript published online ahead of print 11 March 2024];Shrestha;Clin Infect Dis,2024

4. Early estimates of updated 2023–2024 (monovalent XBB.1.5) COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection attributable to co-circulating Omicron variants among immunocompetent adults—increasing community access to testing program, United States, September 2023–January 2024;Link-Gelles;MMWR Morb Mortal Wkly Rep,2024